Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 31.09 |
|---|---|
| High | 31.11 |
| Low | 29.30 |
| Bid | 29.30 |
| Offer | 29.47 |
| Previous close | 31.00 |
| Average volume | 838.48k |
|---|---|
| Shares outstanding | 105.87m |
| Free float | 105.39m |
| P/E (TTM) | -- |
| Market cap | 3.20bn USD |
| EPS (TTM) | -1.58 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 15:19 GMT.
More ▼
- Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026
- Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
- Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors
More ▼
